Guest guest Posted October 30, 2010 Report Share Posted October 30, 2010 " Tasigna is thought to block a signal that causes leukemic cells to develop. The drug was approved in October 2007 for people in the disease's later stages. Users of Tasigna, however, are at greater risk of an abnormal heart rhythm disorder called QT prolongation. The FDA said earlier this year it sanctioned an updated medication guide and other strategies to inform patients and doctors of the drug's risks. " The most common side effects reported during clinical testing include: itching, headache, nausea, fatigue and muscle pain. Serious adverse reactions affecting the blood could include a decrease in bone marrow activity, low blood platelets, anemia and a decrease in infection-fighting white blood cells, the agency said. Tasigna is marketed by Novartis Pharmaceuticals, based in East Hanover, N.J. -- HealthDay. All rights reserved. http://tinyurl.com/2ekqwta FYI, Lottie Duthu Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.